

# HEALTHY U CHIP

## IOR AUTHORIZATION REQUEST FORM

### PHENYLBUTYRATES

Buphenyl®, Pheburane®, Ravicti®

**For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department at 385-425-4052.**

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

**Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.**

**Preferred:** ☐ sodium phenylbutyrate powder, ☐ sodium phenylbutyrate tablets

**Preferred after trial and failure of one of sodium phenylbutyrate powder or tablets:** ☐ Pheburane® (sodium phenylbutyrate)

**Non-preferred:** ☐ Ravicti® (glycerol phenylbutyrate)

Dosing/Frequency: \_\_\_\_\_

#### If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Does the member have a diagnosis of urea cycle disorder requiring chronic management that is confirmed by enzymatic, biochemical or genetic testing?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
2. Does documentation show that the member's condition has not been managed adequately by dietary protein restriction and/or amino acid supplementation alone?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Has a nutritional consultation been performed to assess diet?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Will phenylbutyrate be used in combination with a dietary protein restriction?	<input type="checkbox"/>	<input type="checkbox"/>	
5. Does the requesting provider have experience managing urea cycle disorder?	<input type="checkbox"/>	<input type="checkbox"/>	
6. Is the request for Ravicti®? <b>Please note: For Ravicti®, treatment failure for "bad taste" or "taste aversion" will only be allowed in members ≤11 years old.</b>	<input type="checkbox"/>	<input type="checkbox"/>	
7. Has the member tried and failed or have a contraindication to sodium phenylbutyrate? (Contraindications may include comorbid conditions which limit sodium intake, such as heart failure, renal impairment, hypertension and edema)	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does updated documentation show a continued medical necessity and clinical efficacy of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b>			
Additional information:			
Physician's Signature:			

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy: PHARM-CHIP-058  
 Origination Date: 07/01/2024  
 Reviewed/Revised Date: 06/11/2025  
 Next Review Date: 06/11/2026  
 Current Effective Date: 07/01/2025

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.